

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **JACOBIO PHARMACEUTICALS GROUP CO., LTD.**

**加科思藥業集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1167)**

### **VOLUNTARY ANNOUNCEMENT**

#### **JACOBIO RECEIVED CHINA CDE INVESTIGATIONAL NEW DRUG CLEARANCE FOR PAN-KRAS INHIBITOR JAB-23E73**

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**” or “**Jacobio**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has approved the Investigational New Drug (the “**IND**”) application of its self-developed drug JAB-23E73 (Pan-KRAS Inhibitor). Previously, the IND application in the United States (U.S.) has also been approved by the U.S. Food and Drug Administration (“**FDA**”), and plans to initiate the phase I/IIa clinical trial in advanced solid tumor patients in China and the U.S..

KRAS is widely present in a variety of tumor mutations. About 23%-25% of cancer patients have KRAS mutations. About 2.7 million tumor patients with KRAS-related mutations are added each year worldwide and are expected to benefit from pan-KRAS inhibitor.

JAB-23E73 can inhibit both the active (“**On**”) and inactive (“**Off**”) states of KRAS and with no obvious inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73’s preclinical data has showed a good pharmacokinetic profile.

## **About Jacobio**

Jacobio is committed to developing and providing new and innovative products and solutions to improve patients' health. Our pipeline revolves around novel molecular targets on six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our immunostimulatory antibody-drug conjugate (iADC) Platform.

**Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** There is no assurance that JAB-23E73 will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. Please visit [www.jacobiopharma.com](http://www.jacobiopharma.com) for more information.

By Order of the Board  
**JACOBIO PHARMACEUTICALS GROUP CO., LTD.**  
**Yinxiang WANG**  
*Chairman*

Hong Kong, September 26, 2024

*As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Dr. Te-li CHEN as non-executive Director, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.*